GlassScriptPhysician profile
Oscar A Mendez
NPI 1164520243
$5,285.43
in general payments reported to CMS, 2019-2025
44 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $509 · 2021: $1,342 · 2022: $881 · 2023: $752 · 2024: $639 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,418.14 | 2021-2024 | |
| Astellas Pharma US INC | $348.16 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $345.36 | 2019-2025 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $334.56 | 2019-2021 | |
| Novo Nordisk INC | $277.08 | 2019-2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $263.92 | 2019-2025 | |
| Pfizer INC. | $262.75 | 2019-2025 | |
| Heartflow, INC. | $224.91 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.73 | 2019-2024 | Jardiance |
| Horizon Therapeutics Plc | $141.98 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $140.62 | 2019-2024 | Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.22 | 2019-2024 | Xifaxan |
| Ethicon INC. | $112.31 | 2022 | |
| Boston Scientific Corporation | $108.97 | 2019 | |
| Abiomed | $93.75 | 2023 | Impella |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$686,601.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Mendez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.